SCHEMBL5741590

SCHEMBL5741590

COc1cccc(OCC(=O)N2CCCC2C(=O)O)c1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.64
MEN1 O00255 5/20 0.64
PSMD14 O00487 1/20 0.57
GAA P10253 1/20 0.56
LMNA P02545 1/20 0.53
CPT2 P23786 5/20 0.52
CPT1A P50416 5/20 0.52
SMN1; SMN2 Q16637 2/20 0.51
ALDH1A1 P00352 2/20 0.51
CYP1A2 P05177 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C19 P33261 1/20 0.51
KDM4E B2RXH2 1/20 0.50
DGAT1 O75907 1/20 0.49
HRH3 Q9Y5N1 1/20 0.49
CHRNB4 P30926 1/20 0.49
CHRNA3 P32297 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5741583 1.00 KMT2A (0.64) KMT2AMEN1PSMD14GAALMNA
SCHEMBL6794547 0.94 ALDH1A1 (0.57) KMT2AMEN1PSMD14CPT2CPT1A
SCHEMBL6794537 0.94 ALDH1A1 (0.57) KMT2AMEN1PSMD14CPT2CPT1A
SCHEMBL6788120 0.90 KMT2A (0.53) KMT2AMEN1PSMD14CPT2CPT1A
SCHEMBL6788116 0.90 KMT2A (0.53) KMT2AMEN1PSMD14CPT2CPT1A
SCHEMBL5741161 0.88 ALDH1A1 (0.58) KMT2AMEN1PSMD14CPT2CPT1A
SCHEMBL5741156 0.88 ALDH1A1 (0.58) KMT2AMEN1PSMD14CPT2CPT1A
SCHEMBL6787573 0.87 KMT2A (0.53) KMT2AMEN1PSMD14CPT2CPT1A
SCHEMBL6787567 0.87 KMT2A (0.53) KMT2AMEN1PSMD14CPT2CPT1A
SCHEMBL5743864 0.86 ALDH1A1 (0.63) KMT2AMEN1CPT2CPT1ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6531612-B2 Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis HOFFMAN-LA ROCHE INC. 2003-03-11 US claimed
US-20010008901-A1 Nitrile derivatives that inhibit cathepsin K F. HOFFMANN-LA ROCHE AG (CH) 2001-07-19 US claimed
EP-1244621-B1 NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS HOFFMANN LA ROCHE (CH) 2006-09-13 EP disclosed
US-6531612-B2 Pyrrolidine-2-carboxylic acid cyano-methyl amide derivatives useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis HOFFMAN-LA ROCHE INC. 2003-03-11 US disclosed
EP-1244621-A1 NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2002-10-02 EP disclosed
US-20010008901-A1 Nitrile derivatives that inhibit cathepsin K F. HOFFMANN-LA ROCHE AG (CH) 2001-07-19 US disclosed
WO-2001047886-A1 NITRILE DERIVATIVES AS CATHEPSIN K INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2001-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010008901-A1 Nitrile derivatives that inhibit cathepsin K CTSK, CTSH, CTSS KMT2A 4729/4885MEN1 1236/4885PSMD14 2629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.